OverviewSuggest Edit

Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. The Company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer.

TypePrivate
Founded2003
HQUtrecht, NL
Websitemerus.nl
Employee Ratings4.2

Latest Updates

Employees (est.) (Sept 2021)159
Job Openings8
Cybersecurity ratingAMore

Key People/Management at Merus

Bill Lundberg

Bill Lundberg

President, Chief Executive Officer & Principal Financial Officer, Executive Director
Andrew Joe

Andrew Joe

SVP & Chief Medical Officer
Lex Bakker

Lex Bakker

SVP & Chief Development Officer
John de Kruif

John de Kruif

SVP & Chief Technology Officer
Mark Iwicki

Mark Iwicki

Non-Executive Director
Peter B. Silverman

Peter B. Silverman

EVP, General Counsel and Head of Utrecht
Show more

Merus Office Locations

Merus has offices in Utrecht and Cambridge
Utrecht, NL (HQ)
62 Yalelaan
Utrecht, NL (HQ)
H.R. Kruytgebouw 8 Padualaan
Cambridge, MA, US
139 Main St #302
Show all (3)

Merus Financials and Metrics

Summary Metrics

Founding Date

2003

Merus total Funding

$149.3 m

Merus latest funding size

$79.14 m

Time since last funding

6 years ago

Merus investors

Merus's latest funding round in April 2015 was reported to be $79.1 m. In total, Merus has raised $149.3 m
Show all financial metrics

Merus Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Merus Online and Social Media Presence

Embed Graph

Merus Company Culture

  • CEO Rating

    A-

    80/100

  • Compensation

    D

    55/100

Learn more on Comparably

Merus News and Updates

Merus Announces Publication in Nature Communications on MCLA-145’s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the novel mechanism of action (MOA) of MCLA-145, t…

Merus to Participate in William Blair's Biotech Focus Conference 2021

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer …

Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)

-  61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data cutoff date-  Encouraging early clinical activity observed, with confirmed responses in 5 of 12 patients with pancreatic cancer (42%) and in 13 of 45 patients across severa…

Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

-   51 patients with NRG1+ cancer have been treated, including 33 patients evaluable for response, as of the January 12, 2021, data cutoff date-   Encouraging early clinical activity observed, with confirmed partial responses in 4 of 10 patients with pancreatic cancer (40%) and in 9 of 33 patients a…

Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced new collaborations in Israel, Italy and Spain to ex…

Merus to Participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer o…
Show more

Merus Blogs

Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 26, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., Chief Executive

Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , April 28, 2021 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the

Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer

Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer Content Import Mon, 11/09/2020 - 08:03 Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer November 9, 2020 at 8:00 AM EST This release …

Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors

Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors Content Import Mon, 10/12/2020 - 17:00 Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical T…

Merus Announces Financial Results for the Second Quarter and Provides Business Update

Merus Announces Financial Results for the Second Quarter and Provides Business Update Content Import Thu, 08/06/2020 - 16:11 Merus Announces Financial Results for the Second Quarter and Provides Business Update August 6, 2020 at 4:07 PM EDT This release is a b…

Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer

Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer Content Import Mon, 07/27/2020 - 08:02 Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancreatic Cancer July 27, 2020 at 8:00 AM EDT …
Show more

Merus Frequently Asked Questions

  • When was Merus founded?

    Merus was founded in 2003.

  • Who are Merus key executives?

    Merus's key executives are Bill Lundberg, Andrew Joe and Lex Bakker.

  • How many employees does Merus have?

    Merus has 159 employees.

  • Who are Merus competitors?

    Competitors of Merus include Kromaspects Scitec Solutions, Entera Bio and Catalyst Pharmaceuticals.

  • Where is Merus headquarters?

    Merus headquarters is located at 62 Yalelaan, Utrecht.

  • Where are Merus offices?

    Merus has offices in Utrecht and Cambridge.

  • How many offices does Merus have?

    Merus has 3 offices.